Global Growth Hormone Deficiency Treatment Market - 2024 - 2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	176 Pages	DataM Intelligence 4Market Research LLP	January, 2025	DTAM19508023

Best Price Guarantee
Price	from $4,350
Length	176 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	January, 2025
SKU	DTAM19508023

Global Growth Hormone Deficiency Treatment Market - 2024 - 2032

The global growth hormone deficiency treatment market reached US$ 6.9 billion in 2024 and is expected to reach US$ 9.2 billion by 2032, growing at a CAGR of 12.1% during the forecast period 2024-2032.

Growth hormone deficiency (GHD) is a condition caused by the inadequate secretion of growth hormone (GH) from the anterior pituitary gland.. Growth hormone deficiency can occur due to genetic mutation and even due to the result of the pituitary gland damage.

Market Dynamics: Drivers & Restraints

Increasing development of innovative solutions

The rising development of innovative solutions is expected to drive the growth hormone deficiency treatment market. The growing development of innovative solutions is a key factor driving the growth of the growth hormone deficiency (GHD) market. New, more effective treatments are improving the management of GHD, with advancements such as better delivery systems like smart pens, which increase patient convenience and adherence. Moreover, the continuous innovation in growth hormone treatments is driving new regulatory approvals and expanding treatment indications, including for pediatric and adult patients and those with conditions like adult-onset growth hormone deficiency. For instance, in April 2023, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval for a new indication for Sogroya (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg for the treatment of children aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone. With this new indication, Sogroya becomes the first and only once-weekly growth hormone (GH) treatment for children and adults.

Developing solutions with new formulations is expected to gain traction and contribute to the overall market. This expansion of treatment options broadens the patient population and contributes to the market's growth.

Complications associated with the growth hormone deficiency treatment

The complications and side effects associated with the growth hormone deficiency treatment are expected to hamper the overall market growth. This is due to the result of adverse reactions proceeding with the treatment. Common adverse effects include joint pain, muscle discomfort, and edema, which can lead to patient dissatisfaction and discontinuation of therapy. This could result in the reduced usage of the drugs and products that are being manufactured for growth hormone deficiency patients.

Segment Analysis

The global growth hormone deficiency treatment market is segmented based on type, treatment, route of administration, distribution channel, and region.

Type:

Pharmacological therapy segment is expected to dominate the global growth hormone deficiency treatment market share

The pharmacological therapy segment is expected to hold a major portion of the growth hormone deficiency market due to its proven effectiveness and widespread use. Recombinant growth hormone (rGH) therapies have long been the gold standard for treating GHD, providing significant benefits in terms of growth stimulation, improved bone density, and overall metabolic function.

Advances in drug formulations, such as long-acting growth hormone treatments and improved delivery systems like needle-free injectors and smart pens, have made these therapies more convenient and patient-friendly, further driving their adoption. For instance, in June 2023, Pfizer Inc. and OPKO Health Inc. received the U.S. Food and Drug Administration (FDA) approval for its NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for the treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

Additionally, the introduction of biosimilars, which are more affordable alternatives to branded rGH products, is expanding access to treatment and increasing market penetration. As the number of GHD diagnoses continues to rise globally, the demand for pharmacological treatments remains strong, with continuous innovation leading to new regulatory approvals and expanded indications. These factors position the pharmacological therapy segment to maintain its dominance in the market, meeting the growing demand for effective GHD management.

Geographical Analysis

North America is expected to hold a significant position in the global growth hormone deficiency treatment market share

North America is expected to hold a dominant position in the global growth hormone deficiency market due to several significant factors. The region benefits from high awareness of GHD, advanced diagnostic technologies, and well-established healthcare infrastructure, which leads to early diagnosis and prompt treatment. North American patients have greater access to cutting-edge growth hormone therapies, such as recombinant growth hormone and long-acting formulations, ensuring effective treatment options.

Additionally, the presence of leading pharmaceutical companies and research institutions in the U.S. drives innovation and continuous development of new treatment options. Thus, the above factors position North America to maintain a dominant share of the global GHD treatment market.

Competitive Landscape

The major global players in the growth hormone deficiency treatment market include Pfizer Inc., Sandoz AG, Novo Nordisk Inc., Eli Lilly and Company, Ferring, Genentech, Inc., Merck KGaA (EMD Serono, Inc.), Reliance Life Sciences, AnkeBio Co., Ltd and Omicron Pharma among others.

Key Developments
• In December 2023, Ascendis Pharma A/S announced positive topline results from foresiGHt, its Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and safety of TransCon hGH (lonapegsomatropin) with placebo and daily hGH (human growth hormone, somatropin) in adults with growth hormone deficiency (GHD).

Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Growth Hormone Deficiency Treatment Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Type; 3.2. Snippet by Application; 3.3. Snippet by End-User; 3.4. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Increasing development of innovative solutions; 4.1.2. Restraints; 4.1.2.1. Complications associated with the growth hormone deficiency treatment; 4.1.3. Opportunity; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter’s Five Force Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Patent Analysis; 5.5. Regulatory Analysis; 5.6. SWOT Analysis; 5.7. Unmet Needs
6. By Type: 6.1. Introduction; 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type; 6.1.2. Market Attractiveness Index, By Type; 6.2. Pediatric*; 6.2.1. Introduction; 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 6.3. Adult
7. By Treatment: 7.1.1. Introduction; 7.1.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 7.1.1.2. Market Attractiveness Index, By Treatment; 7.1.2. Pharmacological Therapy*; 7.1.2.1. Introduction; 7.1.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.1.3. Recombinant Human Growth Hormone Therapy; 7.1.4. Human Pituitary Gland Extracts; 7.1.5. Others
8. By Route of Administration: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 8.1.2. Market Attractiveness Index, By Route of Administration; 8.2. Intravenous*; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Intramuscular; 8.4. Others
9. By Distribution Channel: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 9.1.2. Market Attractiveness Index, By Distribution Channel; 9.2. Hospital Pharmacy*; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Online Pharmacy; 9.4. Retail Pharmacy
10. By Region: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 10.1.2. Market Attractiveness Index, By Region; 10.2. North America; 10.2.1. Introduction; 10.2.2. Key Region-Specific Dynamics; 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.2.7.1. U.S.; 10.2.7.2. Canada; 10.2.7.3. Mexico; 10.3. Europe; 10.3.1. Introduction; 10.3.2. Key Region-Specific Dynamics; 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.3.7.1. Germany; 10.3.7.2. U.K.; 10.3.7.3. France; 10.3.7.4. Spain; 10.3.7.5. Italy; 10.3.7.6. Rest of Europe; 10.4. South America; 10.4.1. Introduction; 10.4.2. Key Region-Specific Dynamics; 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.4.7.1. Brazil; 10.4.7.2. Argentina; 10.4.7.3. Rest of South America; 10.5. Asia-Pacific; 10.5.1. Introduction; 10.5.2. Key Region-Specific Dynamics; 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.5.7.1. China; 10.5.7.2. India; 10.5.7.3. Japan; 10.5.7.4. South Korea; 10.5.7.5. Rest of Asia-Pacific; 10.6. Middle East and Africa; 10.6.1. Introduction; 10.6.2. Key Region-Specific Dynamics; 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment; 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape: 11.1. Competitive Scenario; 11.2. Market Positioning/Share Analysis; 11.3. Mergers and Acquisitions Analysis
12. Company Profiles: Key Market Players; 12.1. Pfizer Inc.*; 12.1.1. Company Overview; 12.1.2. Product Portfolio; 12.1.2.1. Product Description; 12.1.2.2. Product Key Performance Indicators (KPIs); 12.1.2.3. Historic and Forecasted Product Sales; 12.1.2.4. Product Sales Volume; 12.1.3. Financial Overview; 12.1.3.1. Company Revenue’s; 12.1.3.2. Geographical Revenue Shares; 12.1.3.3. Revenue Forecasts; 12.1.4. Key Developments; 12.1.4.1. Mergers & Acquisitions; 12.1.4.2. Key Product Development Activities; 12.1.4.3. Regulatory Approvals etc.; 12.1.5. SWOT Analysis; 12.2. Sandoz AG; 12.3. Novo Nordisk Inc.; 12.4. Eli Lilly and Company; 12.5. Ferring; 12.6. Genentech, Inc.; 12.7. Merck KGaA (EMD Serono, Inc.); 12.8. Reliance Life Sciences; 12.9. AnkeBio Co., Ltd; 12.10. Omicron Pharma; * Similar data will be provided for each market player.; Emerging Market Players; 12.11. Genexine, Inc.*; 12.11.1. Pipeline Products Description; 12.11.2. Product Key Performance Indicators (KPIs); 12.11.3. Key Activities; 12.11.4. Market Entry Timelines; 12.11.5. Product Penetration Rate; 12.11.6. Sales Estimation and Projections; 12.12. JCR Pharmaceuticals Co., Ltd.; 12.13. Ascendis Pharma; 12.14. BioNTech SE.; 12.15. Philogen S.p.A.; * Similar data will be provided for each market player.; LIST NOT EXHAUSTIVE
13. Appendix: 13.1. About Us and Services; 13.2. Contact Us